LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

ConclusionDetection and quantification ofEGFR mutations in circulating tumor DNA using the highly sensitive BEAMing method should greatly assist in optimizing treatment decisions for advanced NSCLC patients.

Source: Cancer Medicine - July 23, 2021 Category: Cancer & Oncology Authors: Pilar Garrido, Luis Paz ‐Ares, Margarita Majem, Teresa Morán, José Manuel Trigo, Joaquim Bosch‐Barrera, Rosario Garcίa‐Campelo, José Luis González‐Larriba, José Miguel Sánchez‐Torres, Dolores Isla, Núria Viñolas, Carlos Camps Tags: ORIGINAL RESEARCH Source Type: research